We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Device-Related Concerns Do Not Prevent Favorable Exubera Vote
Device-Related Concerns Do Not Prevent Favorable Exubera Vote
September 16, 2005
Pfizer and sanofi-aventis’ potential breakthrough diabetes drug Exubera has received the green light from an FDA advisory panel, which voted 7-2 Sept. 8 to recommend approval for the inhaled insulin powder.